Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients

J Rheumatol. 2015 Oct;42(10):1993-4. doi: 10.3899/jrheum.150230.

Authors

Sara Monti¹, Silvia Breda², Vittorio Grosso², Monica Todoerti², Carlomaurizio Montecucco², Roberto Caporali²

Affiliations

¹ Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Piazzale Golgi 2, 27100 Pavia, Italy. sara.saramonti@gmail.com.
² Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Piazzale Golgi 2, 27100 Pavia, Italy.

PMID: 26429207
DOI: 10.3899/jrheum.150230

No abstract available

Publication types

Letter
Comment

MeSH terms

Antirheumatic Agents / administration & dosage*
Arthritis, Rheumatoid / drug therapy*
Female
Humans
Immunoconjugates / administration & dosage*
Male

Substances

Antirheumatic Agents
Immunoconjugates